Cassandra N. Moore, M.D.
Velez MG, Kosiorek HE, Egan JB, McNatty AL, Riaz IB, Hwang SR, Stewart GA, Ho TH,
Moore CN
, Singh P, Sharpsten RK, Costello BA, Bryce AH. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep; 25 (3):479-483 Epub 2021 July 22
View PubMed
Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R,
Moore CN
, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. Prostate. 2022 Sep; 82(12):1202-1209. Epub 2022 Jun 02.
View PubMed
Nafissi NN, Kosiorek HE, Butterfield RJ,
Moore C
, Ho T, Singh P, Bryce AH. Evolving Natural History of Metastatic Prostate Cancer. Cureus. 2020 Nov 14; 12 (11):e11484
View PubMed
Armstrong AJ, Creel P, Turnbull J,
Moore C
, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2008 Oct 1; 14 (19):6270-6
View PubMed
Moore CN
, George DJ. Update in the management of patients with hormone-refractory prostate cancer. Curr Opin Urol. 2005 May; 15 (3):157-62
View PubMed
.
Mayo Clinic Footer